4.8 Article

Metabolic Labeling Strategy Boosted Antibacterial Efficiency for Photothermal and Photodynamic Synergistic Bacteria-Infected Wound Therapy

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 14, Issue 41, Pages 46362-46373

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.2c15759

Keywords

antibacterial therapy; metabolic labeling strategy; photothermal therapy (PTT); photodynamic therapy (PDT); bacterial biofilm

Funding

  1. National Science Foundation of China [81801749]
  2. Science and Technology Innovation Program of Hunan Province Huxiang Young Talents Plan [2021RC3106]
  3. Key Research and Development Program of Hunan Province, China [2022SK2053]

Ask authors/readers for more resources

Pathogenic bacteria infections pose a significant risk to human health, necessitating alternative antibacterial strategies. This study developed a metabolic labeling photosensitizer that can be incorporated into the bacterial wall, enhancing antibacterial efficiency. The photosensitizer demonstrated good water solubility, biological safety, and activity in degrading bacterial biofilms.
Pathogenic bacteria infections bring about a substantial risk to human health. Given the development of antibiotic-resistance bacteria, alternative antibacterial strategies with great inactivation efficiency and bacteria-binding ability are extremely attractive. In this work, a metabolic labeling photo sensitizer, prepared by the coupling of commercial IR820 and D- propargylglycine (a type of D-amino acid, DAA) via a straightforward one-step incubation (IR820-DAA), could metabolically be incorporated into the bacterial wall via enzymatic reactions, thus enhancing antibacterial efficiency. The laser energy at 808 nm could make IR820-DAA a synergistic photothermal/ photodynamic agent for efficient antibacterial therapy and wound healing. Furthermore, IR820-DAA exhibits good water solubility and biological safety for clinical translation and even possesses biofilm degradation activity toward methicillin-resistant Staphylococcus aureus (MRSA). Overall, the proposed IR820-DAA holds great promise as a nonantibiotic tool for the treatment of bacteria-related diseases and offers a blueprint for building the precise synergistic antibacterial therapeutic platform.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available